1218 results found
Despite improvements in vaccine uptake in Aboriginal and Torres Strait Islander people, adults experience greater rates of influenza hospitalisation than non-Indigenous adults of the same age.
The objective of the CTCS Grant scheme is to support high-quality clinical trials and cohort studies that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health.
The objective of the Ideas Grant scheme is to support innovative research projects addressing a specific question(s).
A major achievement for Associate Professor Shannon Simpson was the recent establishment of PELICAN (Prematurity’s Effects on the Lungs In Children and Adults Network), which she co-chairs with Dr Jenny Hallberg from the Karolinska Institute in Sweden.
Aboriginal and Torres Strait Islander health evidence-practice policy gap reports. An evidence-practice/policy gap is the difference between what is known from the best available research evidence and what is practised in reality (through delivery of medical care or drafting of policies or guidelines).
CAS NUMBERS 335-67-1 (PFOA), 1763-23-1 (PFOS), 355-46-4 (PFHxS), 375-73-5 (PFBS), 62037-80-3 and 13252-13-6 (GenX Chemicals)(Public Consultation draft October 2024)
NHMRC-accredited Research Translation Centres are leading centres of excellence and collaboration in health and medical research, research translation, research-infused education and training and outstanding health care.
Professor Morgan is Lead of the Neuroscience of Speech research group at Murdoch Childrens Research Institute (MCRI) and Head of Speech Pathology at the University of Melbourne. She is also one of the guideline developers for MCRI’s first Clinical practice guideline for the management of communication and swallowing disorders following paediatric traumatic brain injury for children 0 to 18 years of age (communication and swallowing guideline).
Professor Sarah Larkins has focused on improving equity in health care services in rural, remote and Indigenous populations since a medical education placement in the Northern Territory highlighted the tremendous inequities in health care access in the region.
Pharmaxis Ltd is an Australian pharmaceutical research company established in 1998. It listed on the Australian Securities Exchange (ASX) in 2003. The business focuses on new therapies to treat inflammation and fibrosis with a portfolio of products at various stages of development and approval. With origins in clinical research, this Australian-owned start up successfully competes in an international market.
While progress has been made globally in reducing the impact of tuberculosis (TB), and while Australia has achieved a TB rate among the lowest reported, the South-East Asian region remains a global TB ‘hot spot’. Australia is well placed to help countries in our region deal with TB as we have world-class domestic systems for disease surveillance and control in human and animal health, and a strong track record of cooperation with countries in the region, including on primary health care. Research by a number of Australian research institutions has contributed to regional improvements to TB detection, prevention and treatment, and has demonstrated the possibility of the rapid reduction in TB prevalence within neighbouring countries.